BACKGROUND: Cisplatin and cetuximab are both systemic therapies commonly used in combination with radiation (RT) for the definitive treatment of head and neck cancers, but their comparative efficacy is unclear. METHODS: Patients with locoregionally advanced (American Joint Committee on Cancer stage III-IVB) squamous cell carcinomas of the oropharynx, larynx, or hypopharynx were identified in the Surveillance, Epidemiology, and End Results-Medicare database. Patients received either cisplatin or cetuximab concurrent with RT, as determined by Medicare claims. The primary study outcome was head and neck cancer-specific mortality (CSM) analyzed with competing risks. Filtering, propensity score matching, and multivariable Fine-Gray regression were used to adjust for differences between the cisplatin and cetuximab cohorts, including age, comorbidity, and cycles of systemic therapy received. RESULTS: The total cohort consisted of 1395 patients, of whom 786 (56%) received cisplatin and 609 (44%) received cetuximab; the median follow-up was 3.5 years in the patients who remained alive. In the cetuximab cohort, CSM was significantly higher than in the cisplatin cohort (39% vs 25% at 3 years; P < .0001). In the matched cohorts (n = 414), the adjusted hazard ratio of CSM for cetuximab was 1.65 (95% confidence interval, 1.30-2.09; P < .0001) relative to cisplatin, corresponding to an absolute difference of approximately 10% in both CSM and overall survival at 3 years. Cetuximab was associated with less dysphagia, more dermatitis, and a similar incidence of mucositis. CONCLUSIONS: In this sizeable, national patient population, treatment with cetuximab was associated with significantly higher CSM than cisplatin. These results suggest that cisplatin may be the preferred chemotherapeutic agent in this setting. Cancer 2018;124:4486-4494.
INTRODUCTION
In the United States, head and neck cancer accounted for an estimated 64,690 malignancies and 13,740 deaths in 2018 1 ; globally, it is the sixth most common cancer. 2 Approximately 60% of patients present with locally or regionally advanced (but nonmetastatic) disease. 3 These patients are likely to receive multimodality treatment that includes radiation therapy (RT), delivered definitively or postoperatively, often in combination with systemic therapy, to improve locoregional control and survival. The benefit of concurrent platinum-based chemoradiation (mainly using cisplatin) over RT alone has been demonstrated repeatedly for high-risk postoperative patients in multiple clinical trials [4] [5] [6] [7] and a large meta-analysis.
Cancer December 1, 2018 the head and neck based on results from an international phase 3 trial demonstrating significantly improved locoregional control and overall survival for the combination of cetuximab and RT compared with RT alone 10, 11 for cancers of the oropharynx, larynx, and hypopharynx. Since its approval, cetuximab has been used increasingly to treat patients with an indication for concurrent chemoradiation, 12 especially those for whom there is concern regarding the toxicity of platinum-based chemotherapy, such as frail or elderly patients. 12 However, cetuximab also is gaining use in younger, fitter patients because of the perceived potential for lesser toxicity, with the implicit assumption that oncologic outcomes will not be compromised.
However, despite the status of cisplatin and cetuximab as the 2 most widely administered radiosensitizers in head and neck cancer, their relative effectiveness is unclear, because no large randomized trial of cetuximab-based versus cisplatin-based chemoradiation has been published to date. Therefore, their direct comparison remains a central, unanswered question in head and neck oncology, and it is the subject of multiple active randomized studies in carefully selected populations. 9 To address this gap in knowledge, we investigated comparative outcomes of definitive, concurrent chemoradiation with cisplatin or cetuximab in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, comprising a large, national cohort that reflects real-world practice patterns and outcomes.
MATERIALS AND METHODS

Data Source
The National Cancer Institute (NCI)-sponsored SEER program is an authoritative database of all incident cancers aggregated from 17 regional registries that cover 30% of the US population. 13, 14 The NCI and the Centers for Medicare and Medicaid Services cosponsor the linked SEER-Medicare database, which enables ascertainment of specific diagnoses and procedures using International Classification of Diseases (ICD) and Healthcare Common Procedure Coding System codes across time. All patient data were de-identified. This study was approved by the Stanford University Institutional Review Board.
Cohort Identification
We queried the 2016 linkage of the SEER-Medicare database (spanning cases diagnosed through December 2013) for nonmetastatic, locally or regionally advanced (stage III-IVB) squamous cell carcinomas of the oropharynx, larynx, and hypopharynx. Cases were included from 2004 onward, when American Joint Committee on Cancer sixth edition staging became available in SEER. Disease site was determined using the ICD for Oncology, third edition (ICD-O-3) code; the ICD-O-3/World Health Organization 2008 site recode, and Collaborative Stage schema (Supporting Table 1 ). All patients received definitive RT according to the SEER registry. Patients were required to have both Medicare Parts A and B and no health maintenance organization for 12 months before and after diagnosis (or until death, if sooner) to ensure adequate capture of Medicare claims. To analyze a more uniform population, only patients enrolled in Medicare for age were included, and patients must not have had a prior diagnosis of head and neck cancer.
Because SEER provides the month and year of diagnosis but not the date, the first of the month was treated as the date of diagnosis to ensure that all cancer therapy would occur subsequent to diagnosis. The RT start was defined as the first instance after diagnosis of 2 separate RT claims (Supporting Table 2 ) occurring within 10 days of each other; and the end of RT was defined as a lapse ≥10 days without radiation claims. RT duration was required to be between 35 to 80 days. Patients were required to receive either cisplatin (Healthcare Common Procedure Coding System codes J9060, J9062, and C9418) or cetuximab (codes J9055 and C9215), and not both (whether concurrently or sequentially), in the 12 months after diagnosis. Patients who were switched from cisplatin to cetuximab or vice versa were excluded (n = 28). In addition, the first claim for cisplatin or cetuximab was required to be within 100 days of diagnosis, and Cancer December 1, 2018 chemotherapy and RT start were required to be within 21 days of each other to exclude the use of induction chemotherapy. Table 1 summarizes the algorithm used for cohort identification.
Determination of Study Variables and Outcomes
Study variables that were obtained directly from the SEER database included patient age, sex, race, geographic SEER region, census tract poverty level, marital status, disease site, and American Joint Committee on Cancer tumor (T) and lymph node (N) classification. Comorbidity was calculated with the Charlson comorbidity index, as previously described, 15 using an algorithm published by the NCI. 16 Supporting Table 3 lists claims codes for intensity-modulated RT, smoking/tobacco use, other chemotherapeutic agents, and diagnosis of dysphagia, dermatitis, and mucositis. Because a difference in the amount of systemic therapy received (or tolerated) by patients may confound cancer outcomes, we measured the number of . 30 1 108 (14) 170 (28) 91 (22) 89 (21) ≥2 182 (23) 163 (27) 120 (29) 102 (25 230 (29) 154 (25) 117 (28) 111 (27) >20% 165 (21) 128 (21) 96 (23) 88 (21 Cancer December 1, 2018 chemotherapy cycles using Medicare claims within 80 days of the start of chemotherapy. The number of chemotherapy cycles was determined from the number of claims, because actual pharmacologic dosing data were unavailable. For cetuximab, the number of cycles was the number of cetuximab claims. For cisplatin, a dosing interval of 20 days was used to separate patients into 2 distributions corresponding to cisplatin either every 3 weeks or weekly, and the number of cycles was then derived from the number of cisplatin claims. Receipt of more systemic therapy was defined as ≥7 cycles of cetuximab, ≥6 cycles of weekly cisplatin, or ≥2 cycles of cisplatin every 3 weeks. These cutoffs were based on randomized trial evidence and retrospective analyses, 10, [17] [18] [19] Abbreviations: AHR, adjusted hazard ratio; CI, confidence interval; CSM, cancer-specific mortality; IMRT, intensity-modulated radiotherapy.
Cancer December 1, 2018 which also matched the median number of cycles of each chemotherapy received in our cohort. Patients who received fewer cycles were labeled as having received less systemic therapy. The primary study outcome was head and neck cancer-specific mortality (CSM), which was determined by the SEER cause-specific death classification and the SEER cause of death to site recode field (codes 20010-20100, 22010, and 22020). A secondary outcome was overall survival. For the 2016 SEER-Medicare linkage, patient follow-up was through December 2014.
Statistical Analysis
Baseline characteristics were compared using the chisquare test or the Wilcoxon rank-sum test. The cumulative incidence of head and neck CSM was estimated in the presence of other-cause mortality as a competing risk and was compared using the Gray test. 20 To adjust for differences in baseline characteristics between the cisplatin and cetuximab cohorts, propensity score matching was performed using a 1:1 nearest neighbor method, as previously described. 20 Overall survival was analyzed using the Kaplan-Meier method and was compared using the log-rank test. For multivariable regression, the proportional hazards model of Fine and Gray was used to estimate adjusted hazard ratios for CSM in the presence of other-cause mortality as a competing risk. Cox regression was used for overall survival. MATLAB version R2016b (MathWorks, Inc, Natick, MA) and R version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria) were used for calculations. All statistical tests were 2-sided.
RESULTS
The entire cohort consisted of 1395 patients, of whom 786 (56%) received cisplatin and 609 (44%) received cetuximab. The baseline characteristics of this cohort are listed in Table 2 . Cetuximab recipients were generally older, more likely to have a nonzero comorbidity score, and more likely to receive intensity-modulated RT, among other differences. The median follow-up for patients who remained alive was 3.5 years.
In the entire cohort, head and neck CSM was significantly higher among those who received cetuximab compared with those who received cisplatin (39% vs 25% at 3 years; P < .0001) (Fig. 1) . A sensitivity analysis to exclude receipt of other chemotherapeutic agents (a taxane, 5-fluorouracil, or carboplatin) from the date of cancer diagnosis until 3 months after the end of RT (which occurred in 166 patients, or 11.9% of the total cohort) produced the same findings. On subgroup analysis by disease site, cetuximab was associated with significantly increased CSM for oropharynx cancers, which represented the majority of tumors in this study (P < .0001) (Supporting Fig. 1A) , and nonoropharynx cancers analyzed in aggregate produced the same result (P = .007) (Supporting Fig. 1B) . When the larynx and hypopharynx subgroups were further analyzed separately, their numbers were considerably smaller compared with those for sites in the oropharynx, such that their outcomes did not reach significance or were of borderline significance (P = .07 and P = .04, respectively) (Supporting Fig.  1C,D) . Subgroup analysis according to tumor (T) and lymph node (N) classification produced similar results (Supporting Figs. 2 and 3) .
To address differences in the amount of chemotherapy administered that might influence CSM, we performed a sensitivity analysis restricted to patients who received more systemic therapy, defined as ≥7 cycles of cetuximab, ≥6 cycles of weekly cisplatin, or ≥2 cycles of cisplatin every 3 weeks, as suggested by the number and interval of chemotherapy claims (because the actual dose administered was unavailable; see Materials and Methods, above). Patients who received fewer cycles were labeled as receiving less systemic therapy and were excluded from the sensitivity analysis. We observed that, as before, CSM was significantly increased for cetuximab compared with cisplatin either weekly or every 3 weeks (P < .0001), whereas there was no significant difference between ≥6 cycles of weekly cisplatin and ≥2 cycles of cisplatin every 3 weeks (P = .70) (Fig.  2 ). An additional sensitivity analysis using an alternate cutoff of ≥5 cycles for weekly cisplatin produced the same findings.
To further adjust for differences in baseline characteristics between the cisplatin and cetuximab groups, propensity score matching was performed. After matching, patient and tumor characteristics were well balanced ( Table 2 ). In the matched cohorts (n = 414), CSM remained significantly elevated for patients who received cetuximab compared with those who received cisplatin (39% vs 26% at 3 years; P = .0001) (Fig. 3) . By contrast, there was no difference in other-cause mortality (P = .85), suggesting equitable comorbidity in the matched cohorts. Moreover, overall survival was significantly lower in the matched cetuximab cohort, with a median of 33 versus 54 months (47% vs 59% at 3 years; P = .0001) (Fig. 4) .
On Fine-Gray regression in the matched cohorts, the adjusted hazard ratio of CSM for cetuximab was 1.65 (95% confidence interval [CI], 1.30-2.09; P < .0001).
Cancer December 1, 2018 Other significant covariates included T and N classification, age, and larynx and hypopharynx sites (Table 3) . On Cox regression, the adjusted hazard ratio of overall mortality for cetuximab was 1.57 (95% CI, 1.30-1.90; P < .0001).
Finally, we analyzed the comparative acute toxicities associated with receipt of cisplatin or cetuximab in the matched cohorts, as determined by claims corresponding to a diagnosis of dermatitis, mucositis, or dysphagia within 3 months from the initiation of RT. Compared with the matched cisplatin cohort, the matched cetuximab cohort had a significantly lower relative risk (RR) of dysphagia (RR, 0.83; 95% CI, 0.74-0.94; P = .003), increased dermatitis (RR, 2.71; 95% CI, 1.89-3.90; P < .0001), and no difference in mucositis (RR, 1.03; 95% CI, 0.82-1.30; P = .81).
DISCUSSION
Multiple randomized trials have demonstrated that concurrent cisplatin with RT is superior to RT alone. [5] [6] [7] [8] Similarly, results from a large randomized trial indicated that concurrent cetuximab with RT is superior to RT alone. 10, 11 However, the comparative efficacy of these 2 agents is uncertain. To our knowledge, the current study is the first national population-based analysis of patient outcomes for definitive cisplatin-based versus cetuximab-based chemoradiation. Cetuximab was associated with a significantly higher incidence of head and neck CSM. Our findings persisted after propensity score matching and multivariable analysis to adjust for differences in baseline characteristics. In the matched cohorts, cetuximab was associated with an absolute difference of approximately 10% in overall survival and CSM at 3 years. Furthermore, we observed that receipt of cetuximab was associated with significantly less dysphagia, more dermatitis, and no difference in mucositis within 3 months of RT.
Although the patients who received cetuximab tended to be older and frailer than those who received cisplatin, we addressed this potential source of confounding using 3 different and complementary methodologies. First, the primary endpoint was CSM (rather than overall survival), which we analyzed using a competing risks approach. Second, we controlled for the number of chemotherapy cycles delivered, although actual pharmacologic dosing data were unavailable. Third, we measured comorbidity using the Charlson index and then applied propensity score matching to balance the cisplatin and cetuximab groups, followed by multivariable regression in the matched cohorts. It is worth noting that deaths from other causes were similar, suggesting equitable comorbidity after matching.
Our results complement and expand upon the existing literature comparing cisplatin versus cetuximab concomitant with RT. To date, the only randomized comparison is the phase 2 trial by Magrini et al that Cancer-specific mortality (CSM) is illustrated in patients who received ≥7 cycles of cetuximab (cetux) (n = 407), ≥6 cycles of weekly cisplatin (cis Q1W) (n = 300), or ≥2 cycles of cisplatin every 3 weeks (cis WQ3) (n = 288).
Cancer December 1, 2018 was discontinued after enrolling only 70 patients. 21 The slow accrual of that trial underscores the difficulty of investigating our study question in a randomized fashion. Both 2-year local control (80% vs 53%) and cancer-specific survival (81% vs 68%) favored the cisplatin arm in that study, although neither reached significance because of limited statistical power. In addition, several single-institution, retrospective series and a 2014 meta-analysis reported significantly better locoregional control and survival outcomes for cisplatin relative to cetuximab, [22] [23] [24] although this is not universally the case. 25 Prior randomized studies bypassed a direct comparison, instead evaluating the potential benefit of combining these 2 agents. Radiation Therapy Oncology Group (RTOG) study 0522 demonstrated that RT with concurrent cetuximab and cisplatin was more toxic and was not more efficacious than RT with cisplatin alone. 26 The reciprocal question of platinum added to a cetuximab backbone was investigated in the French Head and Neck Oncology and Radiotherapy Group (GORTEC) 2007-01 trial, in which patients with stage III through IVB disease who had relatively low lymph node burden (N0-N2a) and received RT plus cetuximab were randomized to groups that did or did not receive carboplatin/5-fluorouracil. In a preliminary report, the carboplatin/5-fluorouracil arm had significantly higher locoregional control and progression-free survival than the cetuximab-only arm. 27 Taken together, the results from those 2 trials suggest the nonequivalence of cetuximab-based and platinum-based therapy.
One strength of our study is the use of a population-based cohort with a large sample size reflecting diverse, real-world patterns of care across multiple centers. In addition, we applied competing risks analysis, filtering, propensity matching, and multivariable modeling to address bias. Nonetheless, as with all observational studies, the primary limitation is its retrospective nature; although our results are provocative, they remain hypothesis-generating. Another limitation is that SEER lacks data on RT details (such as fields, dose, or fractionation) and patterns of failure (such as local vs distant). Furthermore, SEER-Medicare does not have information on the actual dose of pharmacologic agents administered; this is an inherent limitation of claims-based studies. Therefore, we estimated the extent of chemotherapy based on the number and interval of chemotherapy claims. Although it as an imperfect surrogate for true chemotherapy intensity, this approach has been used previously in population-based comparative effectiveness analyses. 28 Finally, our analysis of toxicity is not comprehensive, and further analysis of toxicities will be explored in more detail as the focus of future investigations.
SEER also does not have human papillomavirus (HPV) status, which may be associated with oropharyngeal cancer and portends a significantly better prognosis. Cancer December 1, 2018 However, cetuximab reportedly benefits oropharynx cancer regardless of HPV status. 29 In our study, the increased CSM for cetuximab was apparent in both oropharynx and nonoropharynx cancers. Similarly, a subset analysis of HPV-associated oropharynx cancer from the trial reported by Magrini and colleagues still favored cisplatin (2-year local control, 100% vs 73%; cancer-specific survival, 100% vs 78%). 30 A single-institution, retrospective series also reported better outcomes with cisplatin than with cetuximab after accounting for HPV status, 31 although other centers have not observed a difference in this population. 32 At least 3 active phase 3 trials (RTOG 1016, Trans-Tasman Radiation Oncology Group [TROG]12.01, and De-ESCALaTE [Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV-Positive Oropharyngeal Squamous Cell Carcinoma]) are comparing RT plus cetuximab versus cisplatin specifically for HPV-associated oropharyngeal cancer. However, outside of this highly selected patient population, there are no current randomized trials comparing cisplatin-based versus cetuximab-based chemoradiation.
Overall, our current findings are consistent with a growing body of evidence. Results from the Magrini et al trial, RTOG 0522 and GORTEC 2007-01, multiple single institutional series, and a meta-analysis all have pointed toward the nonequivalence of EGFR-targeted and platinum-based concurrent therapy during RT. The relative effectiveness of cetuximab and cisplatin is a central question in head and neck oncology, especially given the increasing focus on cost effectiveness and the upward trend in cetuximab use over time. 12 Until randomized data become available, our current study adds to a collective literature addressing this gap in knowledge. Further study is warranted, in both the oropharynx and nonoropharynx cancer populations, to ensure that the most effective and least toxic treatment is prescribed.
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